Clinical trial

Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A

NCT06643819

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-10-14

PhasePHASE3

Study timeline

Study start (actual)2024-10-14Date precision: day

Registry last updated2025-12-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Essential Hypertensionunresolved

Interventions

Sacubitril∙Valsartan(dose maintenance)DRUG

Sacubitril∙Valsartan(dose increasing)DRUG

ValsartanDRUG · verified · RxNorm: valsartan

Sponsors & collaborators

Chong Kun Dang Pharmaceuticallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06643819 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.